{"name":"Biose","slug":"biose","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"D-chiro-inositol","genericName":"D-chiro-inositol","slug":"d-chiro-inositol","indication":"Polycystic ovary syndrome (PCOS)","status":"phase_2"},{"name":"anti-arrhythmic drug therapy","genericName":"anti-arrhythmic drug therapy","slug":"anti-arrhythmic-drug-therapy","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Dual Anti Platelet Therapy","genericName":"Dual Anti Platelet Therapy","slug":"dual-anti-platelet-therapy","indication":"Acute coronary syndrome","status":"phase_3"}]}],"pipeline":[{"name":"D-chiro-inositol","genericName":"D-chiro-inositol","slug":"d-chiro-inositol","phase":"phase_2","mechanism":"D-chiro-inositol is involved in insulin signaling and glucose metabolism.","indications":["Polycystic ovary syndrome (PCOS)"],"catalyst":""},{"name":"Dual Anti Platelet Therapy","genericName":"Dual Anti Platelet Therapy","slug":"dual-anti-platelet-therapy","phase":"phase_3","mechanism":"Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events.","indications":["Acute coronary syndrome","Percutaneous coronary intervention with stent placement","Secondary prevention of myocardial infarction"],"catalyst":""},{"name":"anti-arrhythmic drug therapy","genericName":"anti-arrhythmic drug therapy","slug":"anti-arrhythmic-drug-therapy","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPQk8tT2ZzTmQ0QklrQllaSVAxaDY3NC12TkpRWGVoQWhmSkxBTzZLSWlnaEdEQjUyUzdOUUlBYk9Gc3dKX3puQ1pVWkdGT3VMUWwyOGt6ZWVWbzlsNHprT3NPTTRGNVRQT0JWRV92bDZmcjU2ekZELXZEdFh5cXg5RWhDaTM3bmxtSnByV1VB?oc=5","date":"2025-11-10","type":"pipeline","source":"Yahoo Finance","summary":"US Live Biotherapeutics Market Research 2025, Competitive Analysis of Arrant Bio, 4D Pharma, Cerbios, Biose, Assembly Biosciences, Wacker Chemie, Quay Pharmaceuticals, NIZO, Lonza, Inpac Probiotics - ","headline":"US Live Biotherapeutics Market Research 2025, Competitive Analysis of Arrant Bio, 4D Pharma, Cerbios, Biose, Assembly Bi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFAzZWtPei1jcE5MLTBRTENPY3FJZWd4LUVpRkZHYjlKek52VXRvQjkwUGxRZWRnbmhLWXpIbEktM2Q3OHR5OG1kNHFRbGktcGlWWm5CUG1aeUdJdXFUNFN4QmlucWxQN2gyUkFHQXptTzFhdw?oc=5","date":"2024-04-17","type":"pipeline","source":"Bowman Funeral Directors","summary":"Representative Sue Chew Obituary April 17, 2024 - Bowman Funeral Directors","headline":"Representative Sue Chew Obituary April 17, 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQTnk0VkNCREdmS0YxNWxyUGplYjFlUFFoOE5vcHBPcjZiYTBMbmQ4T3U1VWpVZG5KWnRYdmVKOFo1WGdxNjhRUlludnBDLXpEeWFkdnJ3SzR2aUxxSS1ycEludmtud3FWX0xxY0t6b2ltdEV4MllBc1BRWjVDclVhWlVtMzBjRm1lZFFhaHJ5Mll3dEdqbWRFdkg1M1Vvc0g2dWMxVmxJemRQR1JvTmQ1MThLY0hodldwUlp3b1Vta3FEaGVNanVZZ3ZoMk1adC1mdUlDY3J5cnpwV21F?oc=5","date":"2020-07-16","type":"pipeline","source":"Cathay Capital","summary":"Biose Industrie raises EUR 30 million to strengthen its position as the reference CDMO in the field of microbiota - Cathay Capital","headline":"Biose Industrie raises EUR 30 million to strengthen its position as the reference CDMO in the field of microbiota","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}